Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1

Molecular Cancer Therapeutics

Volumn 14, Issue 3, 2015, Pages 704-712

  Nakanishi, Yoshito ^a   Akiyama, Nukinori ^a   Tsukaguchi, Toshiyuki ^a   Fujii, Toshihiko ^a   Satoh, Yasuko ^a   Ishii, Nobuya ^a   Aoki, Masahiro ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BAI1 ASSOCIATED PROTEIN 2 LIKE 1; BAR PROTEIN; BINDING PROTEIN; CH 5183284; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEBIO 1347; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RB1 PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; IRTKS PROTEIN, HUMAN; ONCOPROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER PATIENT; CARCINOGENESIS; CARCINOGENICITY; CELL STRUCTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DIMERIZATION; DRUG EFFICACY; ENZYME ACTIVITY; ESOPHAGUS CANCER; FEMALE; FIBROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL CANCER; GENE EXPRESSION; GENE FUSION; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; STOMACH CANCER; TUMOR SUPPRESSOR GENE; 3T3 CELL LINE; ANIMAL; BLADDER TUMOR; CELL LINE; CELL TRANSFORMATION; GENETICS; HCT116 CELL LINE; HEK293 CELL LINE; LUNG TUMOR; METABOLISM; PHOSPHORYLATION; RAT; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FIBROBLASTS; HCT116 CELLS; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICROFILAMENT PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84929247289     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0927-T     Document Type: Article

References (36)

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identificationofthe transforming EML4-ALK fusion geneinnon-small-cell lung cancer. Nature 2007;448:561-6.
2. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
3. Takahashi M, Cooper GM. ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 1987;7:1378-85.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
5. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90.
6. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29.
7. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010;70:2085-94.
8. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
9. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998;78:1143-53.
10. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
11. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-62.
12. Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lympho-ma syndrome. Nat Genet 1998;18:84-7.
13. Yagasaki F, Wakao D, Yokoyama Y, Uchida Y, Murohashi I, Kayano H, et al. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res 2001;61:8371-4.
14. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2014;59:1427-34.
15. Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 2013;230: 270-6.
16. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012;337:1231-5.
17. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22:795-803.
18. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636-47.
19. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013;123:855-65.
20. Peter BJ, Kent HM, Mills IG, Vallis Y, Butler PJ, Evans PR, et al. BAR domains as sensors ofmembrane curvature: the amphiphysin BAR structure. Science 2004;303:495-9.
21. Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Sakata K, Sase H, et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther 2014;13:2547-58.
22. Ishii N, Harada N, Joseph EW, Ohara K, Miura T, Sakamoto H, et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res 2013;73:4050-60.
23. Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, Tachibana Y, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 2011;17: 3272-81.
24. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma 2011;12: 323.
25. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013;13: 772-87.
26. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
27. Omberg L, Ellrott K, Yuan Y, Kandoth C, Wong C, Kellen MR, et al. Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat Genet 2013;45:1121-6.
28. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495-501.
29. Cui YX, Kerby A, McDuff FK, Ye H, Turner SD. NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner. Blood 2009;113:5217-27.
30. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
31. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4.
32. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436:642.
33. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014;508:118-22.
34. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010;24:2463-79.
35. Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neopla-sia 2013;15:975-88.
36. Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L, et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 2013;32:3059-70.